Macroprolactinemia associated with pituitary macroadenoma: Treatment with quinagolide;Macroprolactinaemiával társuló hypophysismacroadenoma kezelése quinagoliddal

Orvosi Hetilap

Volumn 151, Issue 26, 2010, Pages 1072-1075

  Lakatos, Gergely ^a   Szücs, Nikolette ^a   Kender, Zoltán ^a   Czirják, Sándor ^b   Rácz, Károly ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Orszagos Idegsebeszeti Tudomanyos Intezet Budapest   (Hungary)

Author keywords

dopamine agonist; macroprolactinemia; prolactin producing pituitary adenoma

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GONADOTROPIN; QUINAGOLIDE; SOMATOMEDIN C; TESTOSTERONE;

AGED; AGING; CASE REPORT; DISEASE ASSOCIATION; GONADOTROPIN BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS THYROID SYSTEM; HYPOTHYROIDISM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SHORT SURVEY;

AGED, 80 AND OVER; AMINOQUINOLINES; DOPAMINE AGONISTS; HUMANS; HYPERPROLACTINEMIA; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY NEOPLASMS; PROLACTIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953853594     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28896     Document Type: Short Survey

References (13)

1. Blackman, M. R.: Pituitary hormones and aging. Endocrinol. Clin. N. Am., 1987, 16, 981-984.
2. Iranmesh, A., Mulligan, T., Veldhuis, J. D.: Mechanism subserving the physiological nocturnal hypoprolactinemia of healthy older men: dual decline in prolactin secretory burst mass and basal release with preservation of pulse duration, frequency and interpulse interval - a general clinical research study. J. Clin. Endocrinol. Metab., 1998, 99, 1083-1090.
3. Chahal, J. A. E., Schlechte, J.: Hyperprolactinemia. Pituitary, 2008, 11, 141-146.
4. Sadideen, H., Swaminathan, R.: Macroprolactin: what is it and what is its importance? Int. J. Clin. Pract., 2006, 60, 457-461.
5. Vallette-Kasic, S., Morange-Ramos, I., Selim, A. es mtsai: Macroprolactinemia revisited: a study on 106 patients. J. Clin. Endocrinol. Metab., 2002, 87, 581-588.
6. Hauche, O. M., Rocha, A. J., Maia, A. C. es mtsai: Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol., 2001, 57, 327-331.
7. Toldy E., Locsei Z., Szabolcs I. es mtsai: Macroprolactinemia differencialdiagnosztikai jelentosege hyperprolactinaemiaban. Orv. Hetil., 2003, 144, 2121-2127.
8. Suliman, A. M., Smith, T. P., Gibney, J. es mtsa: Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory defi nition of macroprolactinemia. Clin. Chem., 2003, 49, 1504-1509.
9. Toldy, E., Locsei, Z., Szabolcs, I. es mtsai: Macroprolactinemia: the consequences of a laboratory pitfall. Endocrine, 2003, 22, 267-273.
10. Di Sarno, A., Landi, M. L.: The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin. Endocrinol., 2000, 53, 53-60.
11. Pinto, L. P., Hanna, F. W. F., Evans, L. M. es mtsai: The TSH response to domperidone refl ects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia. Clin. Endocrinol. (Oxf.), 2003, 59, 580-584.
12. Mounier, C., Trouillas, J., Claustrat, B.: Macroprolactinaemia associated with prolactin adenoma. Human Reproduction, 2003, 18, 853-857.
13. Boyle, J. B., McLellan, A. R.: What is the clinical relevance of macroprolactinaemia? A clinical case riport. Endocrine Abstracts, 2003, 6, P16.